Loading…
Employees: 334
Size Evolus (EOLS) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $449M, the 2774th largest of 3,117 United States companies the cockpit tracks. Shares closed at $6.80 on 6 Nov 2026.
Performance Over six months the shares gained 7.0%, against -18.1% for the median peer and -1.1% for the United States market (cap-weighted) — 3rd highest of 19 in its peer set.
Growth Revenue grew 13.9% over the last twelve months (peer median -2.3%); the operating margin is -6.5% (peer median 4.8%).
Valuation It trades at 27.4× forward earnings against a peer median of 20.0× (2nd most expensive of 7).
Capital Return on invested capital runs 28.4 points below its cost of capital (10.1% WACC).
Short interest Short interest is 9.7% of the free float (15 Oct 2026).
Next results Next results expected around 9 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $316M | $297M | $266M | $202M | $149M |
| Revenue growth | — | +12% | +32% | +36% | — |
| Gross profit | $206M | $193M | $180M | $135M | $89.0M |
| EBITDA | -$10.4M | -$28.9M | -$21.2M | -$30.2M | -$55.1M |
| Net income | -$34.3M | -$51.6M | -$50.4M | -$61.7M | -$74.4M |
| Free cash flow | -$18.3M | -$45.7M | -$19.5M | -$34.5M | -$86.5M |
| Capital expenditure | $6.51M | $8.45M | $4.82M | $1.63M | $2.94M |
| Total debt | $165M | $155M | $130M | $127M | $74.4M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | EOLS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -12.8% | -11.7% | 10th lowest of 20 |
| 6-month return | +7.0% | -18.1% | 3rd highest of 19 |
| Distance from 52-week high | -26.9% | -41.5% | 5th highest of 20 |
| Revenue growth (TTM) | +13.9% | -2.3% | 5th highest of 20 |
| Operating margin | -6.5% | 4.8% | 7th lowest of 20 |
| Forward P/E | 27.4× | 20.0× | 2nd most expensive of 7 |
| ROIC minus cost of capital | -28.4 pp | -0.9 pp | lowest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Evolus EOLS | United States | $449M | +7% | +14% | -7% | 27.4× | n/a | n/a |
| Gansu Longshenrongfa Pharmaceutical Industry 300534.SZ | China | $450M | +4% | -21% | 8% | n/a | 23.7% | +28.2% |
| Shanghai Fudan Forward S&T 600624.SS | China | $450M | -4% | -14% | -34% | n/a | n/a | n/a |
| RPG Life Sciences RPGLIFE.NS | India | $448M | +2% | +12% | 18% | n/a | n/a | n/a |
| Aquestive Therapeutics AQST | United States | $454M | -16% | +13% | -114% | n/a | n/a | n/a |
| Gufic Biosciences GUFICBIO.NS | India | $454M | +44% | +17% | 14% | n/a | n/a | n/a |
| Beijing Foyou Pharma 601089.SS | China | $455M | -24% | +5% | 10% | 12.8× | n/a | n/a |
| Synmosa Biopharma 4114.TWO | Taiwan | $442M | +2% | +11% | 11% | n/a | 6.5% | +15.3% |
| Zhejiang Chengyi Pharmaceutical 603811.SS | China | $463M | -21% | +7% | 19% | n/a | 7.1% | +1.3% |
| Zhuhai Rundu Pharmaceutical 002923.SZ | China | $464M | -30% | +14% | 5% | n/a | 2.5% | -1.3% |
| Shanghai Jiaoda Onlly 600530.SS | China | $464M | -22% | -2% | -2% | n/a | 33.5% | -0.9% |
| Teyi Pharmaceutical 002728.SZ | China | $465M | -9% | -7% | 7% | 31.1× | 26.6% | +8.0% |
| Shaanxi Kanghui Pharmaceutical Co 603139.SS | China | $466M | -20% | -21% | -68% | n/a | n/a | n/a |
| Evonile Pharma EVONILE.NS | India | $466M | n/a | -5% | 12% | n/a | 46.5% | -1.5% |
| Harbin Medisan Pharmaceutical 002900.SZ | China | $467M | -13% | -5% | -29% | n/a | n/a | n/a |
| Jiangsu Bioperfectus Technologies 688399.SS | China | $432M | -44% | -8% | -23% | n/a | n/a | n/a |
| Aarti Drugs AARTIDRUGS.NS | India | $430M | +12% | +15% | 11% | 18.9× | 19.7% | +3.5% |
| Beijing Centergate Technologies (Holding) 000931.SZ | China | $430M | -20% | -16% | 2% | 21.2× | 9.9% | +6.7% |
| Zhejiang Huakang Pharmaceutical 605077.SS | China | $470M | -39% | +35% | 4% | 11.1× | n/a | n/a |
| Kexing Biopharm 688136.SS | China | $470M | -38% | -14% | -12% | 25.1× | n/a | n/a |
| BlossomHill Therapeutics BLSM | United States | $429M | n/a | n/a | n/a | n/a | n/a | n/a |